Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Samantha Forner

Citation

Annals of Oncology (2018) 29 (suppl_8): viii58-viii86. 10.1093/annonc/mdy270

Authors

S. Forner, V.R. Sim, J.L. Glendenning, R. Burcombe

Author affiliations

  • Oncology, Maidstone Hospital Maidstone & Tunbridge NHS TRUST, ME16 9QQ - Maidstone/GB
More

Resources

Abstract 1692

Background

Neoadjuvant chemotherapy (NACT) with dual HER2 targeting improved pCR rates (ypT0ypN0) compared with Herceptin plus chemotherapy in the TRYPHAENA and NeoSphere registration trials. Pertuzumab-containing regimens were adopted at KOC following NICE approval (December 2016).

Methods

A retrospective case notes study of 110 (stage 1-3) HER2+ breast cancer patients receiving HER2-directed NACT at KOC was conducted. Age, clinical stage, ER status, treatment regimen and pCR status were recorded.

Results

Single targeting treatment (S) used FEC-TH. Dual targeting (D) regimens were FEC-THP or TCHP. Patients were well matched for age, clinical stage and ER status. Overall, dual targeting increased pCR rates: 62% vs 31% (S). pCR rates were higher with dual targeting regardless of ER or nodal status. The highest pCR rate was seen amongst ER negative patients receiving D (81%). Amongst D regimens, an excess of ER+ patients was seen in the TCHP group (75% TCHP vs 37% FEC-THP). Despite this, pCR rates were comparable (61% TCHP vs 63% FEC-THP). All 9 ER negative patients treated with TCHP achieved pCR (100%) compared with FEC-THP (67%). Table: Demographics and pCR rates for single and dual HER2 targeted NACT.Table: 223P

Single targeting (S)Dual targeting (D)
Time periodOct 15-Nov 17Dec 16-Nov 17
N5555
Age Median (range)55 (36-78)53 (29-77)
Regimen
FEC-TH55
FEC-THP19
TCHP36
ER status
ER + 31 (56%)34 (62%)
ER -24 (44%)21 (38%)
Node status at diagnosis
N + 37 (67%)29 (53%)
N -18 (33%)26 (47%)
pCR [n (%)]17 (31%)34( 62%)
ER + 11 (35%)17 (50%)
ER -6 (25%)17 (81%)
N + 11 (30%)22 (76%)
N -6 (33%)12 (46%)

Conclusions

A substantial increase in pCR rates was observed with dual targeting, regardless of ER and nodal status, reproducing the registration trial data in real world clinical practice. pCR rates were greatest in ER negative patients, regardless of regimen. The small subgroup most likely to achieve pCR were ER negative patients treated with TCHP.

Clinical trial identification

Legal entity responsible for the study

Kent Oncology Centre, Maidstone Hospital.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

R. Burcombe: Honorarium and advisory board: Roche in 2017 for writing an article (BJN) on HER2 directed therapy for MBC. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings